Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration with U.S.-based biotech firm Lycia Therapeutics. This partnership grants Lycia access to Nona’s proprietary lysosomal targeting chimeras (LYTACs) platform, aimed at discovering and developing first-in-class therapeutics that target and degrade extracellular and membrane-bound proteins for challenging, unspecified diseases. Financial terms of the agreement remain undisclosed.
Lycia intends to utilize Nona’s Harbour Mich HCAb fully human antibody transgenic mice platform to identify novel antibodies for its LYTAC protein degrader therapeutics. Nona’s LYTAC technology enables the creation of drugs that effectively address extracellular disease-driving targets, which are often difficult to tackle using traditional antibody and small molecule approaches.- Flcube.com
